Navigation Links
Statement of Ben Anderson, Esq., Regarding Denial of Wyeth's En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
Date:10/15/2010

CINCINNATI, Oct. 15/PRNewswire-USNewswire/ --  "This is a significant decision in a case being watched very closely by regulators, patient advocates and the entire pharmaceutical industry," commented Benjamin H. Anderson, Esq. "We strongly believe arguments were made that an en banc hearing was not necessary and that the three-judge panel had acted correctly in reinstating the plaintiff's claim that the diet drug Redux (commonly known as fen-phen) should never have been marketed to the American people."

Wyeth's en banc petition came after the Sixth Circuit Court of Appeals in August rejected Wyeth's claim that Federal drug regulations preempt Ohio negligence claims. Anderson noted that the case (Oliver Wimbush v. Wyeth et al., # 09-3380) was one of the first to be heard following the U.S. Supreme Court's landmark preemption ruling in Wyeth v. Levine. His firm, Anderson Law Offices, LLC, Cleveland, Ohio, is counsel for the plaintiff.


'/>"/>
SOURCE Anderson Law Offices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cellectis Publishes Its Financial Statement for the First Half of 2010
2. A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
3. Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine
4. Statement from CHPA on Todays FDA Advisory Committee Meeting on Dextromethorphan
5. Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics
6. Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta® to a Broader Pain Population
7. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
8. NCPA Statement on CVS Caremark-Aetna Agreement
9. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
10. Dendreon Statement on CMS National Coverage Analysis
11. NORD Calls for Statement of Policy on Orphan Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology:
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):